Antifibrotic effect of heparin on liver fibrosis model in rats

doi:10.4292/wjgpt.v3.i6.86

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 6

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3629)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

449

HTML

2847

Figures (1-4)

167

Tables (1-2)

166

Sum=3629

Dec 6, 2012 (publication date) through May 18, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastrointest Pharmacol Ther. Dec 6, 2012; 3(6): 86-92
Published online Dec 6, 2012. doi: 10.4292/wjgpt.v3.i6.86

Full Size Figure Download Figure

Figure 3 Mean fibrinogen levels measured terminally (n = 6). Normal control, carbon tetrachloride (CCl₄) control, silymarin (100 mg/kg), heparin (2000 IU/kg), silymarin and heparin (combination) group and control treated animals. ^aP < 0.05, ^bP < 0.01, ^dP < 0.001. A: Normal control vs CCl₄ control; B: CCl₄ control vs treatment group; C: Normal control vs control treated; D: Silymarin vs silymarin and heparin combination group; E: Heparin vs silymarin and heparin combination group.

Citation: Shah B, Shah G. Antifibrotic effect of heparin on liver fibrosis model in rats. World J Gastrointest Pharmacol Ther 2012; 3(6): 86-92
URL: https://www.wjgnet.com/2150-5349/full/v3/i6/86.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v3.i6.86